- Home
- GNTA vs ICCC Comparison
GNTA vs ICCC Comparison
Compare GNTA & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- ICCC
- Stock Information
- Founded
- GNTA 2014
- ICCC 1982
- Country
- GNTA Italy
- ICCC United States
- Employees
- GNTA N/A
- ICCC N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- ICCC Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- ICCC Health Care
- Exchange
- GNTA Nasdaq
- ICCC Nasdaq
- Market Cap
- GNTA 59.7M
- ICCC 55.5M
- IPO Year
- GNTA 2021
- ICCC 1987
- Fundamental
- Price
- GNTA $2.26
- ICCC $6.28
- Analyst Decision
- GNTA
- ICCC
- Analyst Count
- GNTA 0
- ICCC 0
- Target Price
- GNTA N/A
- ICCC N/A
- AVG Volume (30 Days)
- GNTA 2.0M
- ICCC 19.2K
- Earning Date
- GNTA 01-01-0001
- ICCC 11-13-2025
- Dividend Yield
- GNTA N/A
- ICCC N/A
- EPS Growth
- GNTA N/A
- ICCC N/A
- EPS
- GNTA N/A
- ICCC 0.20
- Revenue
- GNTA N/A
- ICCC $28,274,756.00
- Revenue This Year
- GNTA N/A
- ICCC N/A
- Revenue Next Year
- GNTA N/A
- ICCC N/A
- P/E Ratio
- GNTA N/A
- ICCC $30.30
- Revenue Growth
- GNTA N/A
- ICCC 21.75
- 52 Week Low
- GNTA $2.10
- ICCC $3.38
- 52 Week High
- GNTA $10.00
- ICCC $7.60
- Technical
- Relative Strength Index (RSI)
- GNTA 42.17
- ICCC 47.66
- Support Level
- GNTA $2.19
- ICCC $5.95
- Resistance Level
- GNTA $10.00
- ICCC $6.33
- Average True Range (ATR)
- GNTA 0.67
- ICCC 0.27
- MACD
- GNTA -0.09
- ICCC 0.00
- Stochastic Oscillator
- GNTA 1.27
- ICCC 30.23
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.